ValiRx PLC Broker Offer Results & Director/PDMR Subscription

RNS Number : 5679P

ValiRx PLC

10 December 2024

 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 WHICH FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

ValiRx plc

 

("ValiRx" or the "Company")

 

Broker Offer Results and Director/PDMR Subscription

 

Further to the announcement made at 7.00 a.m. on 9 December 2024 by the Company in connection with the Fundraising to raise up to £1,573,000 (before expenses) (the "Fundraise Announcement"), ValiRx, a life science company focusing on early-stage cancer therapeutics and women's health, announces that a total of  38,461,538 Broker Offer Shares have been subscribed for at the Issue Price in connection with the conditional Broker Offer, raising £250,000.

 

Following the closing of the Broker Offer, the total gross proceeds for the Company from the conditional Fundraising, comprising the Placing Shares, the Subscription Shares and the Broker Offer Shares (together the "New Ordinary Shares"), are £1,573,000.

 

Director/PDMR Subscription

As set out in the announcement of 9 December 2024, Mark Eccleston, CEO of the Company has informed the Company that, in addition to his participation in the Subscription, he has subscribed for a further 3,076,923 Broker Offer Shares under the Broker Offer. Details of his shareholdings following completion of the Fundraising and subject to shareholder approval at the General Meeting, are set out below:

 

Name	Number of existing Ordinary Shares and Subscription Shares	Number of Broker Offer Shares	Number of Ordinary Shares on Admission	Percentage of enlarged share capital on Admission
Mark Eccleston	19,669,2641	3,076,923	22,746,187	6.08%

 

¹of which, 9,846,145 New Ordinary Shares have been subscribed for by Mark Eccleston directly, 5,538,470 New Ordinary Shares have been subscribed for by OncoLytika Ltd (a company in which Dr. Eccleston is interested) and 2,307,692 New Ordinary Shares have been subscribed for by Mark Eccleston's partner.

 

Admission

Subject to shareholder approval at the General Meeting, the Company will make an application to the London Stock Exchange plc for th New Ordinary Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission of the New Ordinary Shares will become effective and dealings will commence at 8.00 a.m. on or around 31 December 2024. The New Ordinary Shares will rank pari passu with the Existing Shares.

 

Total Voting Rights

For the purpose of the Disclosure Guidance and Transparency Rules, subject to shareholder approval at the General Meeting and following Admission, the enlarged issued share capital of the Company will comprise 374,348,672 ordinary shares of 0.1 pence each. The Company does not hold any shares in the treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.

 

Capitalised terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Company's announcement of 9 December 2024.

 

 

*** ENDS ***

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR").The Directors of the Company take responsibility for this announcement.

 

 

For more information, please contact:

ValiRx plc   Dr Mark Eccleston, CEO	Tel: [phone] www.valirx.com [e-mail]
Cairn Financial Advisers LLP (Nominated Adviser)   Liam Murray / Ludovico Lazzaretti	Tel: [phone]
Shard Capital Partners LLP (Sole Broker)   Damon Heath	Tel: [phone]
V Formation (Public Relations)   Lucy Wharton - Senior PR Executive Sue Carr - Director	[phone] www.vformation.biz   [e-mail] [e-mail]

 

 

Notes for Editors

 

About ValiRx

 

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

 

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

 

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. 

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

 

For further information, visit: www.valirx.com

 

Cautionary statement

Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

ROIEAKAEFDXLFFA